Earnings Call Intelligence Subscribe
Home › Call Sheets › MDT › Q1'26
Call sheet · Q1'26

Medtronic (MDT)

Q1'26 earnings call · held August 19, 2025 · compared with the Q4'25 call · management-credibility review
8/12
Disclosure score
3 medium, 3 low flags
Financial quality
Bottom line
The sleeper story is Elliott's operational partnership enabling faster M&A and bolder capital allocation - this isn't financial engineering but growth acceleration. While CAS momentum is real at nearly 50% growth, the binding constraint is US market execution, where growth decelerated from 5% to 3.5% despite pipeline acceleration. Martha's most revealing quote: 'I still think Ardian has a chance to even be bigger' than CAS - suggesting renal denervation's 18 million patient market could dwarf ablation's impact. My view changes if Q2 US growth doesn't rebound or if the October 8 Symplicity CMS decision is restrictive on patient population coverage.

The 30-second version

  • Elliott partnership is the REAL story - not financial engineering but operational acceleration
  • CAS momentum is genuine but Ardian could be bigger - renal denervation setup exceeds PFA
  • Diabetes separation financials don't add up - they're giving away growth for margin theater

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$8.9B (+5.4% YoY)$8.6B (+4.8% YoY)Deceleration despite growth driver acceleration
Adjusted EPS$1.62 (+11% YoY)$1.26 (+~6% YoY)Leverage story intact but slowing
CAS Revenue GrowthNearly 30%Nearly 50%+20pp acceleration, reached $1B run rate
Cardiovascular Growth8%7%Slight deceleration off high base
Neuroscience GrowthMid-single digits3%Below trend due to Pelvic Health commercial changes
Diabetes Growth12% (6th consecutive double-digit quarter)8%Deceleration with US weakness vs international strength
US Revenue Growth5% (strongest in 15 quarters)3.5%Momentum stalled despite pipeline acceleration
Adjusted Gross Margin65.1% (-70bps YoY)65.1% (-80bps YoY)Stable sequentially but worsening mix headwinds
R&D Investment GrowthBelow revenue growth+7.7% (100bps above revenue)First time in 4 years R&D outpaced revenue
Affera Sequential GrowthNot disclosedNear 60% sequentialMassive quarter-over-quarter acceleration

Accountability tracked

7 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MDT Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.